Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/16/2003WO2003084485A1 Composition for cell proliferation
10/16/2003WO2003084482A2 Antidepressants and their analogues as long-acting local anesthetics and analgesics
10/16/2003WO2003084481A2 Biological affinity based delivery systems
10/16/2003WO2003084479A2 Large scale methods of producing adenovirus and adenovirus seed stocks
10/16/2003WO2003084475A2 INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
10/16/2003WO2003084473A2 Method of treating cancer
10/16/2003WO2003084464A2 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
10/16/2003WO2003084462A2 Process for preparation of pharmaceutical composition containing antiretroviral protease inhibitor with improved bioavailability
10/16/2003WO2003084351A1 Use of creatine pyruvate for increasing stamina during highly intensive intermittent physical exertion
10/16/2003WO2003084345A1 Composition and method to improve quality and yield of meat products
10/16/2003WO2003084344A2 Method of improving absorption of vitamin e by a pet animal
10/16/2003WO2003084343A2 Method and dietary composition for improving fat digestibility
10/16/2003WO2003084342A2 Method and dietary composition for improving lipid digestibility
10/16/2003WO2003084328A1 Parasite infections
10/16/2003WO2003084312A2 Identification and characterization of an anthocyanin mutant (ant1) in tomato
10/16/2003WO2003070701A3 Syntheses of quinazolinones
10/16/2003WO2003070169A3 Aminodiphosphonate apolipoprotein e modulators
10/16/2003WO2003066030A3 Pharmaceutical tablet
10/16/2003WO2003066029A3 Pharmaceutical dosage form for mucosal delivery
10/16/2003WO2003064407A3 Production of δ9 tetrahydrocannabinol
10/16/2003WO2003062443A3 Novel substituted alkane compounds and uses thereof
10/16/2003WO2003061639A3 Use of glutathione synthesis stimulating compounds in reducing insulin resistance
10/16/2003WO2003061620A3 Peptide-carrying bodies for immune response
10/16/2003WO2003059246A3 Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
10/16/2003WO2003057650A3 Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
10/16/2003WO2003053922A3 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
10/16/2003WO2003053142A3 Highly crosslinked biocidal polystyrene hydantoin particles
10/16/2003WO2003051313A3 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
10/16/2003WO2003050064A3 Mitotic kinesin inhibitors
10/16/2003WO2003049696A3 Glucosamine organic acid adducts
10/16/2003WO2003049676A3 Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer
10/16/2003WO2003048164A3 Adenosine a2a receptor antagonists
10/16/2003WO2003048152A3 Inflammation modulators
10/16/2003WO2003047533A3 Composition for treating the surface of the skin
10/16/2003WO2003047504A3 Prevention and treatment of androgen-deprivation induced osteoporosis
10/16/2003WO2003047493A3 Stabilized reverse micelle compositions and uses thereof
10/16/2003WO2003045952A3 Condensed camptothecins as antitumor agents
10/16/2003WO2003045494A3 Imiquimod therapies
10/16/2003WO2003045414A3 Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections
10/16/2003WO2003043668A3 Conditioning solution for contact lenses
10/16/2003WO2003043616A3 Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
10/16/2003WO2003041660A3 Solubilized topoisomerase poisons
10/16/2003WO2003041643A3 Hsp90-inhibiting zearalanol compounds and methods of producing and using same
10/16/2003WO2003039555A3 Agents for treating lesions of the nervous system
10/16/2003WO2003039469A3 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
10/16/2003WO2003039439A3 Deuterated pyrazolopyrimidinones and drugs containing said compounds
10/16/2003WO2003039231A3 Compounds and methods for treating transplant rejection
10/16/2003WO2003037314A3 Medical compositions for intravesical treatment of bladder cancer
10/16/2003WO2003037311A3 Method for treating retroviral infections
10/16/2003WO2003037271A3 Compounds, pharmaceutical compositions and methods of use therefor
10/16/2003WO2003037159A3 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
10/16/2003WO2003035790A3 Improved method for generating an aerosol
10/16/2003WO2003033678A3 Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
10/16/2003WO2003032969B1 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
10/16/2003WO2003032922A3 Stabilized azithromycin compositions
10/16/2003WO2003031393A3 Carbonyloxy-cyanomethyl compounds as antiparasitic agents
10/16/2003WO2003030814A3 Cross-regulin composition of turmeric-derived tetrahydrocurcuminoids for skin lightening and protection against uvb rays
10/16/2003WO2003029413A3 A novel g protein-coupled receptor, gave 10
10/16/2003WO2003028634A3 Method of treatment using ligand-immunogen conjugates
10/16/2003WO2003026743A3 Opioid formulations having reduced potential for abuse
10/16/2003WO2003026626A3 Modified release dosage forms
10/16/2003WO2003026585A3 Compositions and methods for inhibiting eccrine perspiration in humans
10/16/2003WO2003026492A3 Prevention and treatment of restenosis by local administration of drug
10/16/2003WO2003022260B1 Use of methotrexate and l-arginine for the preparation of a medicament for treatment of uterine myoma
10/16/2003WO2003022218A3 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
10/16/2003WO2003020241A3 Functional powders for oral delivery
10/16/2003WO2003015707A3 Method for treating lung cancers
10/16/2003WO2003015494A3 Tocopherol enriched compositions and amelioration of inflammatory symptoms
10/16/2003WO2003010192A3 An inducer of apoptosis
10/16/2003WO2003008407A3 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
10/16/2003WO2003007802A9 Pharmaceutical combinations of oxycodone and naloxone
10/16/2003WO2003005968A3 Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa
10/16/2003WO2002102307A3 Nucleoside vaccine adjuvants
10/16/2003WO2002100849A3 Novel nitriles useful as reversible inhibitors of cysteine proteases
10/16/2003WO2002100826A3 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
10/16/2003WO2002100382A3 Controlled release dosage forms using acrylic polymer, and process for making the same
10/16/2003WO2002100347A3 Prodrugs of gaba analogs, compositions and uses thereof
10/16/2003WO2002099043A3 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002098899A3 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002097043A3 Wnv core protein/capsid interacting protein and uses of the same
10/16/2003WO2002094745A3 Non-peptidic cyclophilin binding compounds and their use
10/16/2003WO2002094216A3 Delivery of stimulants through an inhalation route
10/16/2003WO2002090493A3 Δ4-desaturase genes and uses thereof
10/16/2003WO2002083110A3 Animal model for evaluating analgesics
10/16/2003WO2002080884A3 Powder inhaler formulations
10/16/2003WO2002079220A3 Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
10/16/2003WO2002072022A3 Substituted tetracycline compounds as antifungal agents
10/16/2003WO2002072009A3 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
10/16/2003WO2002064134A3 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies
10/16/2003WO2002064096A9 Methods of using pyrimidine-based antiviral agents
10/16/2003WO2002059375A3 Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
10/16/2003WO2002056804A3 Presbyopia treatment by lens alteration
10/16/2003WO2002055086A3 Hormone replacement therapy method and its administration form
10/16/2003WO2002045705A3 Regenaration of blood vessels
10/16/2003WO2002042484A3 Method for producing pectin hydrolysis products
10/16/2003WO2002036118A3 Heterocyclic derivatives useful as pharmaceutical agents
10/16/2003WO2002033121A3 Test for the diagnosis of diabetes and compounds for the treatment thereof
10/16/2003WO2002019980A8 Composition of vitamin c and/or vitamin a
10/16/2003WO2002007673A3 Calcilytic compounds
10/16/2003WO2002003978A3 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
1 ... 5307 5308 5309 5310 5311 5312 5313 5314 5315 5316 5317 5318 5319 5320 5321 5322 5323 5324 5325 5326 5327 ... 7860